[1]Amaya-Garrido A, Brunet M, Buffin-Meyer B, et al. Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease[J]. Sci Transl Med, 2023, 15(712): eabn5939.
[2]Huang X W, Wang Y, Qiu Y M, et al. Resveratrol ameliorates high-phosphate-induced VSMCs to osteoblast-like cells transdifferentiation and arterial medial calcification in CKD through regulating Wnt/β-catenin signaling[J]. Eur J Pharmacol, 2022, 925: 174953.
[3]Lu Y, Meng L L, Ren R Q, et al. Paraspeckle protein NONO attenuates vascular calcification by inhibiting bone morphogenetic protein 2 transcription[J]. Kidney Int, 2024, 105(6): 1221-1238.
[4] Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification[J]. Circ Res, 2005, 97(2):105-114.
[5]Ouyang L, Su X Y, Li W X, et al. ALKBH1-demethylated DNA N6-methyladenine modification triggers vascular calcification via osteogenic reprogramming in chronic kidney disease[J]. J Clin Invest, 2021, 131(14): 146985.
[6]Li W X, Feng W J, Su X Y, et al. SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease[J]. J Clin Invest, 2022, 132(1): e150051.
[7]Ding N N, Lv Y D, Su H, et al. Vascular calcification in CKD: New insights into its mechanisms[J]. J Cell Physiol, 2023, 238(6): 1160-1182.
[8]Staruschenko A, Alexander R T, Caplan M J, et al. Calcium signalling and transport in the kidney[J]. Nat Rev Nephrol, 2024, 20(8): 541-555.
[9]Peacock M. Calcium metabolism in health and disease[J]. Clin J Am Soc Nephrol, 2010, 5 Suppl 1: S23-S30.
[10]Pirklbauer M, Schupart R, Mayer G. Acute calcium kinetics in haemodialysis patients[J]. Eur J Clin Invest, 2016, 46(12): 976-984.
[11]Tinawi M. Disorders of calcium metabolism: hypocalcemia and hypercalcemia[J]. Cureus, 2021, 13(1): e12420.
[12]Evenepoel P, Stenvinkel P, Shanahan C, et al. Inflammation and gut dysbiosis as drivers of CKD-MBD[J]. Nat Rev Nephrol, 2023, 19(10): 646-657.
[13]Zhang D L, Wang L Y, Sun F, et al. Is the dialysate calcium concentration of 1.75 mmol/L suitable for Chinese patients on maintenance hemodialysis?[J]. Calcif Tissue Int, 2014, 94(3): 301-310.
[14]LeBeouf A, Mac-Way F, Utescu M S, et al. Effects of acute variation of dialysate calcium concentrations on arterial stiffness and aortic pressure waveform[J]. Nephrol Dial Transplant, 2009, 24(12): 3788-3794.
[15]He Z X, Cui L, Ma C Y, et al. Effects of lowering dialysate calcium concentration on carotid intima-media thickness and aortic stiffness in patients undergoing maintenance hemodialysis: a prospective study[J]. Blood Purif, 2016, 42(4): 337-346.
[16]Lu J R, Yi Y, Xiong Z X, et al. The study of low calcium dialysate on elderly hemodialysis patients with secondary hypoparathyroidism[J]. Blood Purif, 2016, 42(1): 3-8.
[17]Kim S J, Lee Y K, Oh J, et al. Effects of low calcium dialysate on the progression of coronary artery calcification in hemodialysis patients: An open-label 12-month randomized clinical trial[J]. Int J Cardiol, 2017, 243: 431-436.
[18]Masterson R, Blair S, Polkinghorne K R, et al. Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial[J]. Hemodial Int, 2017, 21(1): 19-28.
[19]Lambert O, Couchoud C, Metzger M, et al. Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry[J]. PLoS One, 2020, 15(7): e0235135.
[20]Villa-Bellosta R. Vascular calcification: key roles of phosphate and pyrophosphate[J]. Int J Mol Sci, 2021, 22(24): 13536.
|